Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

ABSTRACT:

Importance

In patients with atherosclerotic cardiovascular disease (ASCVD), guidelines recommend optimizing statin treatment, and consensus pathways suggest use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of statins. Recent trials have provided evidence of benefit in reduction of cardiovascular events with these agents.

Objective

To estimate the percentage of patients with ASCVD who would require a PCSK9 inhibitor when oral lipid-lowering therapy (LLT) is intensified first.

Design, setting, and participants

This simulation model study used a large administrative database of US medical and pharmacy claims to identify a cohort of 10

SUBMITTER: Cannon CP 

PROVIDER: S-EPMC5710173 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature